Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of “Buy” by Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has received an average recommendation of “Buy” from the ten analysts that are presently covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $45.00.

A number of analysts recently commented on DNTH shares. Robert W. Baird started coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 price target for the company. Cantor Fitzgerald initiated coverage on Dianthus Therapeutics in a research report on Thursday, June 27th. They set an “overweight” rating for the company. Raymond James raised their price objective on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a research report on Thursday, April 18th. Lifesci Capital raised Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Finally, HC Wainwright initiated coverage on Dianthus Therapeutics in a research report on Thursday, May 16th. They set a “buy” rating and a $40.00 price objective for the company.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently modified their holdings of the stock. Octagon Capital Advisors LP increased its holdings in Dianthus Therapeutics by 15.4% in the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after buying an additional 74,000 shares in the last quarter. Vestal Point Capital LP bought a new stake in Dianthus Therapeutics in the 4th quarter worth about $1,404,000. Citigroup Inc. bought a new stake in Dianthus Therapeutics in the 3rd quarter worth about $53,000. Virtu Financial LLC bought a new stake in Dianthus Therapeutics in the 1st quarter worth about $390,000. Finally, Hussman Strategic Advisors Inc. bought a new stake in Dianthus Therapeutics in the 1st quarter worth about $630,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Up 3.2 %

Shares of DNTH stock opened at $28.36 on Tuesday. The stock has a fifty day moving average of $25.90 and a 200 day moving average of $24.78. Dianthus Therapeutics has a 52 week low of $6.58 and a 52 week high of $33.77. The firm has a market capitalization of $832.37 million, a price-to-earnings ratio of -4.86 and a beta of 1.89.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The company had revenue of $0.87 million during the quarter, compared to the consensus estimate of $0.48 million. Equities research analysts anticipate that Dianthus Therapeutics will post -2.18 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.